Radiopharm Theranostics Initiates U.S. Phase 2b Imaging Study for Brain Metastasis

The latest update is out from Radiopharm Theranostics Limited ( (AU:RAD) ).

Radiopharm Theranostics has commenced dosing the first patient in a U.S. Phase 2b imaging study using 18F-RAD101 for suspected recurrent brain metastasis. This trial aims to evaluate the diagnostic performance of 18F-RAD101, a novel imaging small molecule targeting fatty acid synthase, in patients with confirmed recurrent brain metastases. The study’s primary objective is to assess the concordance between 18F-RAD101 positive lesions and conventional MRI imaging. The trial underscores Radiopharm’s commitment to advancing diagnostic precision in oncology, potentially improving treatment decisions for over 300,000 patients diagnosed with brain metastasis annually in the U.S.

More about Radiopharm Theranostics Limited

Radiopharm Theranostics is a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for diagnostic and therapeutic applications in areas of high unmet medical need. The company is listed on ASX and NASDAQ and has a pipeline of technologies including peptides, small molecules, and monoclonal antibodies for use in various solid tumor cancers.

YTD Price Performance: -12.50%

Average Trading Volume: 7,218,566

Technical Sentiment Signal: Buy

Current Market Cap: A$49.01M

Find detailed analytics on RAD stock on TipRanks’ Stock Analysis page.